Vizient awards Medasense Innovative Technology contract for PMD-200 pain monitor

Medasense Biometrics said its PMD-200 pain response monitoring system with NOL technology received an Innovative Technology contract from Vizient on Aug. 4, 2026. The award could expand use of objective nociception monitoring in anesthesia care across U.S. hospitals.

Why it matters: - Vizient’s Innovative Technology contract can help speed adoption of PMD-200 in hospitals that want more objective pain monitoring during surgery. - The contract highlights demand for tools that help anesthesia teams personalize analgesia and avoid underdosing or overdosing patients. - Medasense said the award creates a path to bring NOL monitoring to more U.S. hospitals.

What happened: - Medasense Biometrics announced on Aug. 4, 2026, that the PMD-200 pain response monitoring system with NOL technology received an Innovative Technology contract from Vizient. - Vizient is the largest provider-driven healthcare performance improvement company in the U.S. - The contract followed review by hospital experts serving on one of Vizient’s client-led councils. - Vizient’s contract signals to clients that the PMD-200 has unique qualities and potential to improve healthcare delivery.

The details: - The PMD-200 addresses a core anesthesia challenge: measuring a patient’s physiological response to pain while the patient is under general anesthesia and cannot communicate. - The NOL-Nociception Level Index continuously monitors and quantifies nociception, the body’s physiological response to pain. - The system uses AI-powered analysis of multiple physiological signals collected through a proprietary sensor platform placed on the patient’s finger. - Clinical studies have shown NOL-guided analgesia can help personalize analgesic dosing, improve outcomes and reduce postoperative pain. - Medasense says the PMD-200 with NOL technology is the first and only FDA-authorized monitor in the U.S. that objectively measures nociception. - The PMD-200 is used in operating rooms to improve pain management in anesthesia care. - Clinical studies have shown benefits including opioid sparing and reduced post-operative pain. - The PMD-200 is commercially available in the U.S., Europe, Canada, Latin America and Israel. - Medasense’s website is www.medasense.com.

Between the lines: - The award reflects a broader shift in anesthesia toward data-driven pain management instead of relying only on indirect signs and clinician interpretation. - Vizient’s process can matter because its Innovative Technology Program may award contracts outside the competitive bid cycle for products judged to be innovative. - Vizient serves a broad customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers. - Vizient’s portfolio represents more than $156 billion in annual purchasing volume.

What's next: - Medasense said it will use the contract to expand awareness of NOL monitoring across more U.S. hospitals. - The company said the goal is to make objective pain monitoring a routine part of anesthesia care and advance more personalized analgesia and precision medicine. - Hospitals that participate in Vizient’s network may now evaluate the PMD-200 more closely for possible adoption.

The bottom line: - Vizient’s contract gives Medasense a major commercial signal for a pain-monitoring tool aimed at making anesthesia care more precise and measurable.